Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039675 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT01039675 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 51 participants.
The verdict
NCT01039675, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
Interventions
- DRUG 500mcg/25mcg once daily
- DRUG Placebo once daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2010-01-01 |
| Est. Completion | 2010-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01039675
The ClinicalTrials.gov registry entry for NCT01039675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 500mcg/25mcg once daily is the first listed.
NCT01039675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01039675 about?
NCT01039675 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD". The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
What is the current status of trial NCT01039675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2010-01-01. Estimated completion is 2010-04-20.
What interventions are being tested in trial NCT01039675?
The interventions under investigation include: 500mcg/25mcg once daily (DRUG), Placebo once daily (DRUG).
Who is sponsoring clinical trial NCT01039675?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.